The need for pediatric formulations to treat children with HIV

Adrienne F. Schlatter, Andrew R. Deathe, Rachel Vreeman

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Over 3.2 million children worldwide are infected with HIV, but only 24% of these children receive antiretroviral therapy (ART). ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the life and health of infected children. Important causes of poor adherence are formulation- and regimen-specific properties, including poor palatability, large pill burden, short dosing intervals, and the complex storage and transportation of drugs. This review aims to summarize the various regimen- and formulation-based barriers to ART adherence among children to support the need for new and innovative pediatric formulations for antiretroviral therapy (ART). Detailing the arguments both for and against investing in the development of pediatric HIV medications, as well as highlighting recent advances in pediatric ART formulation research, provides a synopsis of the current data related to pediatric ART formulations and adherence.

Original languageEnglish (US)
Article number1654938
JournalAIDS Research and Treatment
Volume2016
DOIs
StatePublished - 2016

Fingerprint

HIV
Pediatrics
Drug Storage
Therapeutics
Virus Diseases
Research

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology and Allergy
  • Infectious Diseases
  • Dermatology

Cite this

The need for pediatric formulations to treat children with HIV. / Schlatter, Adrienne F.; Deathe, Andrew R.; Vreeman, Rachel.

In: AIDS Research and Treatment, Vol. 2016, 1654938, 2016.

Research output: Contribution to journalReview article

Schlatter, Adrienne F. ; Deathe, Andrew R. ; Vreeman, Rachel. / The need for pediatric formulations to treat children with HIV. In: AIDS Research and Treatment. 2016 ; Vol. 2016.
@article{c6a8b6004c964a62a067381fa51be04d,
title = "The need for pediatric formulations to treat children with HIV",
abstract = "Over 3.2 million children worldwide are infected with HIV, but only 24{\%} of these children receive antiretroviral therapy (ART). ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the life and health of infected children. Important causes of poor adherence are formulation- and regimen-specific properties, including poor palatability, large pill burden, short dosing intervals, and the complex storage and transportation of drugs. This review aims to summarize the various regimen- and formulation-based barriers to ART adherence among children to support the need for new and innovative pediatric formulations for antiretroviral therapy (ART). Detailing the arguments both for and against investing in the development of pediatric HIV medications, as well as highlighting recent advances in pediatric ART formulation research, provides a synopsis of the current data related to pediatric ART formulations and adherence.",
author = "Schlatter, {Adrienne F.} and Deathe, {Andrew R.} and Rachel Vreeman",
year = "2016",
doi = "10.1155/2016/1654938",
language = "English (US)",
volume = "2016",
journal = "AIDS Research and Treatment",
issn = "2090-1240",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The need for pediatric formulations to treat children with HIV

AU - Schlatter, Adrienne F.

AU - Deathe, Andrew R.

AU - Vreeman, Rachel

PY - 2016

Y1 - 2016

N2 - Over 3.2 million children worldwide are infected with HIV, but only 24% of these children receive antiretroviral therapy (ART). ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the life and health of infected children. Important causes of poor adherence are formulation- and regimen-specific properties, including poor palatability, large pill burden, short dosing intervals, and the complex storage and transportation of drugs. This review aims to summarize the various regimen- and formulation-based barriers to ART adherence among children to support the need for new and innovative pediatric formulations for antiretroviral therapy (ART). Detailing the arguments both for and against investing in the development of pediatric HIV medications, as well as highlighting recent advances in pediatric ART formulation research, provides a synopsis of the current data related to pediatric ART formulations and adherence.

AB - Over 3.2 million children worldwide are infected with HIV, but only 24% of these children receive antiretroviral therapy (ART). ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the life and health of infected children. Important causes of poor adherence are formulation- and regimen-specific properties, including poor palatability, large pill burden, short dosing intervals, and the complex storage and transportation of drugs. This review aims to summarize the various regimen- and formulation-based barriers to ART adherence among children to support the need for new and innovative pediatric formulations for antiretroviral therapy (ART). Detailing the arguments both for and against investing in the development of pediatric HIV medications, as well as highlighting recent advances in pediatric ART formulation research, provides a synopsis of the current data related to pediatric ART formulations and adherence.

UR - http://www.scopus.com/inward/record.url?scp=84976581060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976581060&partnerID=8YFLogxK

U2 - 10.1155/2016/1654938

DO - 10.1155/2016/1654938

M3 - Review article

VL - 2016

JO - AIDS Research and Treatment

JF - AIDS Research and Treatment

SN - 2090-1240

M1 - 1654938

ER -